# DESCRIPTION

## FIELD OF THE INVENTION

- define invention scope

## BACKGROUND OF THE INVENTION

- introduce antibody structure
- describe antigen binding
- explain effector functions
- detail Fc region interactions
- describe Fc receptor types
- explain FcγRII characteristics
- discuss FcγRII genotypes
- describe FcγRIIa and FcγRIIb differences
- discuss monoclonal antibody therapy
- identify need for modified Fc regions
- summarize limitations of prior art

## SUMMARY OF THE INVENTION

- introduce altered polypeptides
- describe FcγR binding portion
- introduce variant CDR3 region
- describe altered antibodies with variant CDR3 region
- describe altered polypeptides with variant CDR3 region
- introduce specific amino acid substitutions
- describe modified antibody with altered effector function
- describe prevention of proinflammatory mediator release
- introduce human IgG isotype
- describe altered antibodies with increased potency
- introduce modified Fc portion
- describe modified Fc receptor activity
- introduce CD32A receptor
- describe increased inhibition of proinflammatory mediator release
- introduce neutralizing antibody
- describe modified Fc receptor activity with neutralizing antibody
- introduce human IgG1 isotype
- describe amino acid substitution at EU position 328
- describe amino acid substitution at EU position 325
- describe amino acid substitution at EU position 326
- introduce human IgG2 isotype
- describe amino acid substitution at EU position 328
- describe amino acid substitution at EU position 325
- describe amino acid substitution at EU position 326
- introduce human IgG3 isotype
- describe amino acid substitution at EU position 328
- describe amino acid substitution at EU position 325
- describe amino acid substitution at EU position 326
- introduce human IgG4 isotype
- describe altered antibodies with variant CDR3 region and variant Fc region
- describe altered polypeptides with variant CDR3 region and variant Fc region
- define altered polypeptides and antibodies
- describe variant Fc region
- describe heavy chain variable amino acid sequence
- describe light chain variable amino acid sequence
- describe CH2 domain mutations
- describe CDR regions
- describe targeting human CD32A
- describe modified Fc effector activity
- describe binding to target
- describe human IgG1 isotype antibody
- describe VH CDR regions
- describe VL CDR regions
- describe gamma heavy chain constant region substitutions
- describe altered antibody properties
- describe modified versions of existing antibodies
- describe isolated polypeptides with gamma 1 Fc region
- describe production of altered antibodies
- describe numbering of residues in gamma heavy chain
- describe numbering of immunoglobulin variable regions
- describe pharmaceutical compositions
- describe kits

## DETAILED DESCRIPTION OF THE INVENTION

- define altered antibodies
- describe preferred embodiments
- introduce variant CDR3 regions
- summarize altered Fc regions
- motivate modified effector functions
- describe prevention of proinflammatory mediators release
- introduce neutralizing antibodies
- describe altered antibodies binding TLR4/MD-2 receptor complex
- summarize antibodies binding TLR4 and MD-2
- introduce antibodies recognizing toll-like receptors
- describe other suitable altered antibodies

### DEFINITIONS

- define scientific and technical terms
- specify singular and plural terms
- describe cell and tissue culture techniques
- outline molecular biology techniques
- outline protein and oligo- or polynucleotide chemistry and hybridization
- describe recombinant DNA techniques
- describe oligonucleotide synthesis techniques
- describe tissue culture and transformation techniques
- describe enzymatic reactions and purification techniques
- define antibody terms
- describe immunoglobulin molecules
- define antigen-binding site
- describe framework regions
- describe hypervariable regions
- describe complementarity-determining regions
- define epitope
- describe immunological binding properties
- define isolated polynucleotide
- define isolated protein
- describe polypeptide terms
- define naturally-occurring
- describe operably linked
- describe control sequence
- describe polynucleotide
- define twenty conventional amino acids
- describe stereoisoforms of amino acids
- describe unconventional amino acids
- describe polypeptide notation
- define substantial identity
- describe conservative amino acid substitutions
- describe preferred conservative amino acid substitutions
- describe minor variations in amino acid sequences
- describe genetically encoded amino acids
- describe hydrophilic and hydrophobic amino acids
- describe aliphatic-hydroxy family
- describe amide-containing family
- describe aliphatic family
- describe aromatic family
- describe label or labeled
- describe pharmaceutical agent or drug
- define substantially pure
- define altered antibodies
- describe altered antibodies with variant CDR3 regions
- describe altered antibodies with variant Fc regions
- describe inhibition of LPS-induced proinflammatory cytokine production
- describe specific monoclonal antibodies
- describe epitopes recognized by altered antibodies
- describe method for determining epitopic specificity
- describe production of polyclonal or monoclonal antibodies
- describe purification of antibodies
- describe generation of monoclonal antibodies
- describe hybridoma method
- describe immunizing agent
- describe fusion of lymphocytes with immortalized cell line
- describe culture of hybridoma cells
- describe assay for monoclonal antibodies
- describe determination of binding affinity
- describe subcloning of hybridoma cells
- describe growth of hybridoma cells
- describe purification of monoclonal antibodies
- describe recombinant DNA methods for producing monoclonal antibodies
- describe isolation and sequencing of DNA encoding monoclonal antibodies
- describe expression vectors for recombinant monoclonal antibodies
- describe modification of DNA encoding monoclonal antibodies
- describe humanized antibodies
- describe fully human antibodies
- describe production of human antibodies using trioma technique
- describe production of human antibodies using human B-cell hybridoma technique
- describe production of human antibodies using EBV hybridoma technique
- describe production of human antibodies using phage display libraries
- describe production of human antibodies using transgenic animals
- describe production of human antibodies using Xenomouse
- describe method for producing nonhuman host lacking endogenous immunoglobulin heavy chain
- describe method for producing antibody of interest
- describe method for identifying clinically relevant epitope
- describe method for selecting antibody that binds specifically to relevant epitope
- describe expression of single chain antibody
- describe vectors for gene transfer
- describe viral vectors
- describe fusion proteins
- describe chemical conjugates
- describe modes of gene transfer
- define bispecific antibodies
- describe traditional production methods
- summarize purification methods
- introduce antibody variable domains
- describe fusion with immunoglobulin constant domains
- outline expression vector construction
- discuss co-transfection into host organisms
- describe alternative approach for maximizing heterodimer yield
- introduce techniques for generating bispecific antibodies from fragments
- describe chemical linkage methods
- outline leucine zipper technology
- introduce diabody technology
- describe single-chain Fv dimers
- contemplate trispecific antibodies
- describe exemplary bispecific antibodies
- introduce heteroconjugate antibodies
- describe methods for making heteroconjugate antibodies
- contemplate modifying antibody effector function
- describe cysteine residue introduction
- outline homodimeric antibody generation
- introduce dual Fc region engineering
- describe immunoconjugates
- list enzymatically active toxins
- list radionuclides for radioconjugates
- describe conjugate formation using bifunctional agents
- list exemplary bifunctional agents
- describe preferred linkers
- outline linker attributes
- describe immunoliposome formation
- outline liposome composition
- describe Fab' fragment conjugation
- introduce altered antibody use
- describe therapeutic formulations
- outline treatment of immune-related disorders
- list autoimmune diseases
- list inflammatory disorders
- describe treatment of acute inflammation and sepsis
- describe treatment of neurodegenerative autoimmune diseases
- describe treatment of diseases caused by mechanical stress
- define immune-related disorders
- list symptoms of immune-related disorders
- describe efficaciousness of treatment
- outline methods for screening antibodies
- describe use of antibodies in localization and quantitation
- describe use of altered antibodies in isolation and diagnostics
- list detectable substances for antibody detection
- describe therapeutic use of antibodies
- define therapeutically effective amount of antibody
- describe administration of antibodies
- describe pharmaceutical compositions
- outline principles for preparing pharmaceutical compositions
- describe use of antibody fragments
- describe formulation of pharmaceutical compositions
- describe sterilization of pharmaceutical compositions
- describe sustained-release preparations
- describe use of antibodies in detection
- describe labeling of antibodies
- describe biological samples
- describe in vitro and in vivo detection methods
- describe pharmaceutical compositions for administration
- describe carriers and diluents for pharmaceutical compositions
- describe supplementary active compounds
- describe routes of administration
- describe parenteral administration
- describe oral administration
- describe injectable solutions
- describe sterile powders for injectable solutions
- describe oral compositions
- describe tablets, pills, and capsules
- describe ingredients for oral compositions
- describe administration by inhalation
- describe transmucosal and transdermal administration
- describe penetrants for transmucosal and transdermal administration
- describe suppositories and retention enemas
- describe controlled release formulations
- describe biodegradable polymers
- describe liposomal suspensions
- describe dosage unit forms and containers

### EXAMPLES

- introduce generation of monoclonal antibodies
- describe antibody sequences
- test antibody neutralization of LPS-induced IL-8
- evaluate antibody specificity
- introduce humanization of murine monoclonal antibodies
- describe humanized antibody sequences
- test humanized antibody binding to TLR4/MD2
- evaluate humanized antibody inhibition of LPS-induced IL-6
- introduce increasing potency of modified monoclonal antibodies
- describe modification of Fc portion of antibody
- evaluate chimeric antibody neutralization of LPS
- compare murine and chimeric antibody potency
- evaluate antibody binding to Fc gamma receptors
- introduce mutation to disrupt Fc gamma receptor binding
- evaluate mutated antibody potency
- test antibody inhibition of LPS-induced IL-6
- evaluate role of CD32 in antibody potency
- test anti-CD32 antibody blockade of Fc binding
- evaluate CD32A polymorphism effect on antibody potency
- test antibody potency in different CD32A genotypes
- introduce studies on critical region of Fc region
- describe replacement of CH2 domain with human CH2
- evaluate antibody binding to TLR4/MD2
- test antibody potency in human whole blood assay
- evaluate role of CH2 domain in Fc-mediated inhibition
- introduce studies on critical residues of CH2 domain
- describe subdivision of CH2 domain into four parts
- introduce human residues into CH2 domain
- evaluate antibody binding to TLR4/MD2
- test antibody potency in human whole blood assay
- evaluate effect of human residues on Fc-mediated inhibition
- identify critical residues of CH2 domain
- evaluate role of CH2 domain in Fc-mediated inhibition
- summarize findings on Fc-mediated inhibition
- discuss implications for antibody therapy
- conclude importance of Fc region in antibody potency
- finalize discussion of antibody potency
- demonstrate equivalent binding to TLR4/MD2
- evaluate neutralizing capability using human whole blood assay
- conclude inhibitory activity of mouse CH2 domain
- design studies to determine minimum number of residues
- introduce mouse IgG1 CH2 amino acid residues
- express and purify mutant MAbs
- evaluate neutralizing capability of mutant MAbs
- conclude critical residues for inhibitory activity
- design new set of mutants
- express and purify new mutants
- evaluate relative binding affinity of new mutants
- evaluate neutralizing capability of new mutants
- conclude inhibitory activity of new mutants
- evaluate humanized version of 15C1
- compare inhibitory activity of chimeric and humanized versions
- construct mutants based on human or mouse amino acid residues
- evaluate binding affinity of mutants
- evaluate neutralizing capability of mutants
- conclude inhibitory activity of mutants
- test best humanized CH2 mutant
- evaluate implication of CD32 in inhibitory effect
- align CH2 domain of human, mouse, and rat IgG isotypes
- describe CDR3 mutated neutralizing antibodies
- modify CDR3 portion of antibody
- analyze binding of mutants by FACS
- express and purify mutants
- evaluate binding of mutants to TLR4-MD2
- conclude relative affinity of mutants
- describe humanized VH mutant 1 and VL mutant 2
- evaluate binding of humanized mutants
- conclude higher relative affinity of humanized mutants
- describe humanized VH mutant 2 and VL mutant 1
- evaluate binding of humanized mutants
- conclude higher relative affinity of humanized mutants
- describe humanized VH mutant 3 and VL mutant 4
- evaluate binding of humanized mutants
- conclude higher relative affinity of humanized mutants
- describe humanized VH mutant 4 and VL mutant 3
- evaluate binding of humanized mutants

## OTHER EMBODIMENTS

- disclaim limitation

